Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

Схожие документы

• HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
  по: Konecny, G E, et al.
  Опубликовано: (2009)
• Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
  по: Kim, Hwang-Phill, et al.
  Опубликовано: (2009)
• Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
  по: Konecny, G E, et al.
  Опубликовано: (2009)
• The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models
  по: LaBonte, Melissa J., et al.
  Опубликовано: (2011)
• Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
  по: Collantes Maria, et al.
  Опубликовано: (2010-05-01)